Drug Interactions between Adapin and AirDuo Respiclick
This report displays the potential drug interactions for the following 2 drugs:
- Adapin (doxepin)
- AirDuo Respiclick (fluticasone/salmeterol)
Interactions between your drugs
doxepin salmeterol
Applies to: Adapin (doxepin) and AirDuo Respiclick (fluticasone / salmeterol)
MONITOR: Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia. In addition, both classes of drugs have been reported to produce electrocardiographic changes including flattening of the T wave and prolongation of the QTc interval, and these effects may be additive during coadministration.
MANAGEMENT: Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.
References
- "Product Information. Proventil (albuterol)." Schering Corporation PROD (2002):
- "Product Information. Serevent (salmeterol)." Glaxo Wellcome PROD
- "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals PROD (2001):
- "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim PROD (2001):
- "Product Information. Tornalate (bitolterol)." Apothecon Inc (2022):
- "Product Information. Xopenex (levalbuterol)." Sepracor Inc PROD (2001):
- "Product Information. Foradil (formoterol)." Novartis Pharmaceuticals PROD (2001):
- "Product Information. Brovana (arformoterol)." Sepracor Inc (2006):
- "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals (2011):
- "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline (2013):
- "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim (2014):
fluticasone salmeterol
Applies to: AirDuo Respiclick (fluticasone / salmeterol) and AirDuo Respiclick (fluticasone / salmeterol)
Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.
References
- "Product Information. Foradil (formoterol)." Novartis Pharmaceuticals PROD (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia EspaƱola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaciĆ³n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
Drug and food interactions
doxepin food
Applies to: Adapin (doxepin)
GENERALLY AVOID: Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills. Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.
MANAGEMENT: Patients should be advised to avoid alcohol during TCA therapy. Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy. Dosage adjustments may be required.
References
- Dorian P, Sellers EM, Reed KL, et al. "Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction." Eur J Clin Pharmacol 25 (1983): 325-31
- Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
- Sandoz M, Vandel S, Vandel B, Bonin B, Allers G, Volmat R "Biotransformation of amitriptyline in alcoholic depressive patients." Eur J Clin Pharmacol 24 (1983): 615-21
- Ciraulo DA, Barnhill JG, Jaffe JH "Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers." Clin Pharmacol Ther 43 (1988): 509-18
- Seppala T, Linnoila M, Elonen E, Mattila MJ, Makl M "Effect of tricyclic antidepressants and alcohol on psychomotor skills related to driving." Clin Pharmacol Ther 17 (1975): 515-22
- Ciraulo DA, Barnhill JG, Jaffe JH, Ciraulo AM, Tarmey MF "Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls." J Stud Alcohol 51 (1990): 366-72
- Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.